Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7369949 | 0.83 | CA5A (0.43) | CA5AKDM4ESMN1; SMN2LMNACYP2C9 | |
| SCHEMBL31520153 | 0.81 | KDM4E (0.50) | KDM4ELMNACYP2C9L3MBTL1ALDH1A1 | |
| SCHEMBL32669678 | 0.81 | KDM4E (0.50) | KDM4ELMNACYP2C9L3MBTL1ALDH1A1 | |
| SCHEMBL23317588 | 0.80 | CYP11B1 (0.41) | CA5AKDM4ESMN1; SMN2CYP2C9L3MBTL1 | |
| SCHEMBL22230775 | 0.80 | TTR (0.42) | CA5AKDM4ESMN1; SMN2LMNACYP2C9 | |
| SCHEMBL18629884 | 0.80 | GSK3B (0.45) | CYP2C9ALDH1A1MEN1KMT2A | |
| SCHEMBL1644952 | 0.80 | CA5A (0.56) | CA5ASMN1; SMN2LMNACYP2C9ALDH1A1 | |
| SCHEMBL7662707 | 0.76 | VNN1 (0.45) | KDM4ESMN1; SMN2CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL2369495 | 0.76 | S1PR3 (0.51) | CYP11B1CYP11B2ALDH1A1S1PR3MEN1 | |
| SCHEMBL30737737 | 0.76 | S1PR3 (0.51) | CYP11B1CYP11B2ALDH1A1S1PR3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3348557-B1 | IMIDAZO[1,2A]PYRIDINES FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2020-04-29 | — | — | EP | disclosed |
| EP-3348557-B1 | IMIDAZO[1,2A]PYRIDINES FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2020-04-29 | — | — | EP | disclosed |
| US-10399971-B2 | Compound for treating or preventing hyperuricemia or gout | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2019-09-03 | — | — | US | disclosed |
| US-10399971-B2 | Compound for treating or preventing hyperuricemia or gout | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2019-09-03 | — | — | US | disclosed |
| US-20180282321-A1 | COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2018-10-04 | — | — | US | disclosed |
| EP-3348557-A1 | COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd (CN) | 2018-07-18 | — | — | EP | disclosed |
| EP-3348557-A1 | COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd (CN) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017041732-A1 | COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | 江苏新元素医药科技有限公司 | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282321-A1 | COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | SLC10A1, SLC5A1, SLC10A6 | CA5A 1148/4885KDM4E 2487/4885SMN1; SMN2 3361/4885 |
| US-10399971-B2 | Compound for treating or preventing hyperuricemia or gout | SLC10A1, SLC5A1, SLC10A6 | CA5A 1148/4885KDM4E 2487/4885SMN1; SMN2 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.